Holdings
Orbimed Advisors LLC
As of Sep 30, 2026, Orbimed Advisors LLC reported 105 positions worth US$5.15B. Largest: Edgewise Therapeutics, Inc., ADARx Pharmaceuticals, Inc. and Enliven Therapeutics, Inc. What it bought and sold, with each filing.
| Company | Shares | Value as reported | Change | As of |
|---|---|---|---|---|
| Edgewise Therapeutics, Inc. | 15.5M | US$630M | no change | Sep 30, 2026 |
| ADARx Pharmaceuticals, Inc. | 24.2M | US$483M | new | Sep 30, 2026 |
| Enliven Therapeutics, Inc. | 6.78M | US$311M | no change | Sep 30, 2026 |
| Eli Lilly and Company | 258K | US$298M | no change | Sep 30, 2026 |
| Braveheart Bio, Inc. | 12.2M | US$246M | new | Sep 30, 2026 |
| Sinovac Biotech, Ltd. | 2.72M | US$196M | no change | Sep 30, 2026 |
| MBX Biosciences, Inc. | 3.07M | US$180M | −354K | Sep 30, 2026 |
| Merck & Company, Inc. | 946K | US$137M | +283K | Sep 30, 2026 |
| Guardant Health, Inc. | 584K | US$104M | +400 | Sep 30, 2026 |
| ArriVent BioPharma, Inc. | 3.03M | US$91.7M | no change | Sep 30, 2026 |